1. Sustained-release drug composition consisting of peptide microparticles as an active substance and a biocompatible water-soluble polymer, where the peptide and biocompatible water-soluble polymer comprise at least 90% by weight of the microparticles, and the active substance is selected from a ligand from one or more melanocortin receptors ( MC) .2. The composition according to claim 1, where the active substance is selected from a ligand receptor for melanocortin MC4.3. The composition of claim 1, wherein the peptide is Ac-Arg-c (Cys-D-Ala-His-D-Phe-Arg-Trp-Cys) -NH or a pharmaceutically acceptable salt thereof. A composition according to any one of the preceding claims 2 to 3, wherein the active substance is contained in a concentration of from 20 to 70% (w / w) and preferably from 25 to 60% and more preferably from 30 to 50% of the microparticles. The composition of claim 1, wherein the biocompatible water soluble polymer is a biodegradable water soluble polymer. The composition of claim 1, wherein the biocompatible water soluble polymer is a polysaccharide. The composition of claim 1 or 6, wherein the biocompatible water-soluble polymer is a polysaccharide with a molecular weight (MM) of less than 2000 kDa and more preferably less than 1800 kDa. The composition of claim 6, wherein the biodegradable water soluble polymer is a polysaccharide selected from hyaluronic acid or a salt thereof. The composition of claim 8, where the mass ratio of the peptide / sodium hyaluronate in the microparticles is in the range from 3 to 0.25, preferably from 1 to 0.33.10. The composition of claim 1, wherein the microparticles are obtained by spray drying. The composition according to claim 1, where the average microparticle size is in the range from 2 to 50 microns, preferably from 5 to 30 microns. Injection to1. Лекарственная композиция с длительным высвобождением, состоящая из микрочастиц пептида в качестве активного вещества и биосовместимого водорастворимого полимера, где п
